MitoQ administration prevents endotoxin-induced cardiac dysfunction.
about
Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancersOxidative-Nitrosative Stress and Myocardial Dysfunctions in Sepsis: Evidence from the Literature and Postmortem ObservationsMitochondrial Mechanisms in Septic CardiomyopathySepsis-induced Cardiac Mitochondrial Damage and Potential Therapeutic Interventions in the ElderlyInterplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathyMitochondrial oxidative stress in aging and healthspanUnderstanding and preventing mitochondrial oxidative damageCardiopulmonary bypass and oxidative stressExperimental treatments for mitochondrial dysfunction in sepsis: A narrative reviewNutritional countermeasures targeting reactive oxygen species in cancer: from mechanisms to biomarkers and clinical evidenceEnergy crisis: the role of oxidative phosphorylation in acute inflammation and sepsisMitochondrial oxidative stress and mammalian healthspan.Bench-to-bedside review: Targeting antioxidants to mitochondria in sepsis.Mitochondria-targeted antioxidant MitoQ ameliorates experimental mouse colitis by suppressing NLRP3 inflammasome-mediated inflammatory cytokines.Molecular strategies for targeting antioxidants to mitochondria: therapeutic implications.Inhibition of c-Jun-N-terminal kinase increases cardiac peroxisome proliferator-activated receptor alpha expression and fatty acid oxidation and prevents lipopolysaccharide-induced heart dysfunction.Mitochondrial anti-oxidant protects IEX-1 deficient mice from organ damage during endotoxemia.Cardiac aging: from molecular mechanisms to significance in human health and diseaseUbiquinol (reduced Coenzyme Q10) in patients with severe sepsis or septic shock: a randomized, double-blind, placebo-controlled, pilot trial.Coenzyme Q10 deficiency in septic shock patients.The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease.Novel insights into interactions between mitochondria and xanthine oxidase in acute cardiac volume overload.The mitochondria-targeted antioxidant mitoquinone protects against cold storage injury of renal tubular cells and rat kidneys.Mitochondrial ROS Induces Cardiac Inflammation via a Pathway through mtDNA Damage in a Pneumonia-Related Sepsis Model.Redox mechanisms of cardiomyocyte mitochondrial protection.Could Biomarkers Direct Therapy for the Septic Patient?The mitochondria-targeted antioxidant MitoQ attenuates liver fibrosis in mice.Early determinants of pulmonary vascular remodeling in animal models of complex congenital heart diseaseRole of mitochondrial dysfunction and altered autophagy in cardiovascular aging and disease: from mechanisms to therapeutics.Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes.Emerging drugs in sepsis.Mitochondrial medicine for neurodegenerative diseases.Animal and human studies with the mitochondria-targeted antioxidant MitoQ.Polyphenols and human health: a prospectus.Cellular metabolic and autophagic pathways: traffic control by redox signaling.Myocardial energetics in heart failure.The role of mitochondrial dysfunction in sepsis-induced multi-organ failureNanopreparations for organelle-specific delivery in cancerMitochondria-Targeted Antioxidants for the Treatment of Cardiovascular Disorders.Mitochondria and Mitochondrial ROS in Cancer: Novel Targets for Anticancer Therapy.
P2860
Q21198861-92A908CB-59CD-468A-B600-576D38EA7408Q26747626-EAF4280D-5F41-41E0-8529-40ACFBBDEC9FQ26801508-D4C826C4-D3C5-40B9-8C31-141C0A4995BCQ26853544-1EA2FA1C-06F5-4777-8F80-43248AA3F486Q27001165-8436D658-D29D-4AC5-8E5F-CF5438CE0B8FQ27025099-08CE575F-5752-4A40-99BD-723E9E7B8696Q28080331-36EA5331-9F92-4815-9C56-8F72ED5FA831Q28083922-D8313428-7D9C-4CA2-A498-EB07B1855F90Q28392010-2595084F-F0A4-4E4D-9DD2-FF5C2D1C7BAFQ28393187-63171A51-7CDB-43FD-B9D3-344983E8F6C9Q34102154-F0C9A0E6-BA8E-4D8A-95BA-292FC0D519A5Q34104004-75FDDA56-51CB-4A85-B89B-669385300C3FQ34153200-AC89ACEC-E16D-4125-8D81-45178810975CQ34893991-92F70ADB-F75E-4116-BDC2-66C82E4DF558Q35148462-7DFE2A58-4EC0-4F08-87BD-26C0ECEFA800Q35378402-5384F161-40E0-40A7-9954-6879A002619BQ35382736-EA0474BF-9D37-45D6-8900-4B01916A77F1Q35898648-72A57D89-15DD-42DD-A1B6-4F0B09E2369FQ35902883-162F6108-A46B-43CF-BC24-C367D590389AQ35908073-0977D684-455C-4BEB-9138-686E6D771255Q35908404-69936494-839B-4A07-A036-5AABE479EB53Q35998409-889F3C2B-9626-47F2-93AB-EF135409C0B5Q36057168-61E87EE0-0CDE-4757-AB07-9976A4A167B1Q36137078-973987CC-5AE4-4F8A-98C2-167A7CA84474Q36205698-AF18A4AB-1373-4DDA-970D-2D70EEE19D4DQ36852546-730D79D3-4B8C-46EC-9E8A-863213F2C7A1Q36879459-963654F7-4790-4764-AD25-4602EA49B3B8Q37416218-46EEBD73-8E2D-47FF-A1E7-86864771BF9AQ37476530-5C45B4E0-291D-4F98-AC28-A305C090B1DDQ37653023-95277392-1597-42A3-91C8-5A9F149E8848Q37670186-B478337E-621E-49D8-9B5D-30F96E3E6BCCQ37672741-50AC71C7-CB47-402B-8320-7143345EC4BBQ37774684-690C89F1-370B-436D-AFCB-05300704280AQ37934984-51A41C29-0E73-4E28-B010-9FDDBF2B6BC2Q38108973-8B2666B4-07B5-4925-9974-01B307F6226DQ38112349-D2FFF232-C3E4-4658-A55E-E8AC0A043711Q38159424-8C71FDE8-5CFD-4E7F-90AA-A55F071070F6Q38165639-7B3373F9-D39B-4CFF-8113-765887FB210BQ38678059-C716F2BB-245D-4208-AA12-383FD697B68DQ38741503-64CF31DA-772C-4EA9-8D59-F64866DB7AEF
P2860
MitoQ administration prevents endotoxin-induced cardiac dysfunction.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
MitoQ administration prevents endotoxin-induced cardiac dysfunction.
@en
MitoQ administration prevents endotoxin-induced cardiac dysfunction.
@nl
type
label
MitoQ administration prevents endotoxin-induced cardiac dysfunction.
@en
MitoQ administration prevents endotoxin-induced cardiac dysfunction.
@nl
prefLabel
MitoQ administration prevents endotoxin-induced cardiac dysfunction.
@en
MitoQ administration prevents endotoxin-induced cardiac dysfunction.
@nl
P2860
P1476
MitoQ administration prevents endotoxin-induced cardiac dysfunction.
@en
P2093
G S Supinski
L A Callahan
P2860
P304
P356
10.1152/AJPREGU.90902.2008
P577
2009-08-05T00:00:00Z